Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of...

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...

Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 London, UK, 10 July 2022 – Novo Nordisk announced the...

PureWay® Compliance Partners With Medical Device and Pharmaceutical Manufacturers to Bring Safe and Environmentally Friendly Disposal to Patients At-Home HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Each year, approximately 9 million patients receive at least 3 billion injections outside of healthcare facilities.  These medications are used to manage a...